Long-term effect of home-based pulmonary rehabilitation in severe asthma.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
10 2019
Historique:
received: 03 06 2019
revised: 20 08 2019
accepted: 22 08 2019
pubmed: 4 9 2019
medline: 26 8 2020
entrez: 4 9 2019
Statut: ppublish

Résumé

Home-based pulmonary rehabilitation (PR) has demonstrated its effectiveness amongst patients with chronic obstructive pulmonary disease (COPD) but has never been investigated in severe asthma. In a retrospective study, we included 28 patients with severe asthma (61.5 ± 16.2 years, FEV1: 51.4 ± 17.3%) and 164 matched COPD patients (64.3 ± 11.6 years, FEV1: 47.7 ± 15.5%) who had completed a home-based PR program and pursued at least 12 months of follow-up. The number of steps performed during a 6-min stepper test (6MST), the Hospital Anxiety and Depression (HAD) scores, and the Visual Simplified Respiratory Questionnaire score (VSRQ) were compared between baseline, the post-PR period (post-PR) and after 12 months of follow-up (M12) within each group. The evolution of the 6MST, HAD and VSRQ values between baseline, post-PR and M12 was compared between severe asthma and COPD patients. In the severe asthma group, the 6MST was higher post-PR (504 ± 150, p = 0.043) and at M12 (538 ± 163, p = 0.016) compared with baseline (450 ± 148). The VSRQ score was higher at M12 (39.0 ± 18.6, p = 0.049) but not post-PR (38.7 ± 15.8, p = 0.119) in comparison with baseline (32.2 ± 12.4). There was no difference in the HAD scores between baseline, post-PR and M12. PR outcome was not significantly different between severe asthma and COPD patients at short and long term (p > 0.05). In severe asthma, home-based PR is associated with improved exercise tolerance and quality of life on a long-term basis but does not modify anxiety and depression.

Identifiants

pubmed: 31479806
pii: S0954-6111(19)30279-3
doi: 10.1016/j.rmed.2019.08.015
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-41

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Jean-Marie Grosbois (JM)

FormAction Santé, F-59840, Pérenchies, France.

Jeremy Coquart (J)

Univ Rouen, Faculté des Sciences du Sport, CETAPS, EA 3832, F-76821, Mont Saint Aignan, France.

Stephanie Fry (S)

CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Référence Constitutif des Maladies Pulmonaires Rares, F-59000, Lille, France; Inserm, CNRS, Institut Pasteur de Lille, U1019, UMR 8204, CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France.

Olivier Le Rouzic (O)

CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Référence Constitutif des Maladies Pulmonaires Rares, F-59000, Lille, France; Inserm, CNRS, Institut Pasteur de Lille, U1019, UMR 8204, CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France; Univ Lille, F-59000, Lille, France.

Thomas Grosbois (T)

CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Référence Constitutif des Maladies Pulmonaires Rares, F-59000, Lille, France.

Benoit Wallaert (B)

CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Référence Constitutif des Maladies Pulmonaires Rares, F-59000, Lille, France; Inserm, CNRS, Institut Pasteur de Lille, U1019, UMR 8204, CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France; Univ Lille, F-59000, Lille, France.

Cecile Chenivesse (C)

CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Référence Constitutif des Maladies Pulmonaires Rares, F-59000, Lille, France; Inserm, CNRS, Institut Pasteur de Lille, U1019, UMR 8204, CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France; Univ Lille, F-59000, Lille, France. Electronic address: cecile.chenivesse@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH